---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000973"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-13T23:54:49.650086+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aldeyra announces positive Phase 3 INVIGORATE-2 trial for reproxalap in allergic conjunctivitis

## Summary
- Primary endpoint met: ocular itching reduction at all 11 timepoints (p<0.0001).
- Key secondary endpoint ocular redness achieved (p=0.004); tearing and total severity score also significant (p<0.0001).
- Results consistent with prior trials; no safety concerns; 130 of 131 patients completed.
- Reproxalap NDA for dry eye disease under FDA review with PDUFA date of November 23, 2023.

## SEC filing metadata
- accession: 0001157523-23-000973
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752323000973/0001157523-23-000973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752323000973/a53421176.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000973
- JSON: https://secwatch.observer/filing/0001157523-23-000973.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.